GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Mabion SA (WAR:MAB) » Definitions » Price-to-Free-Cash-Flow

Mabion (WAR:MAB) Price-to-Free-Cash-Flow : 10.95 (As of May. 21, 2025)


View and export this data going back to 2010. Start your Free Trial

What is Mabion Price-to-Free-Cash-Flow?

As of today (2025-05-21), Mabion's share price is zł10.12. Mabion's Free Cash Flow per Share for the trailing twelve months (TTM) ended in Sep. 2024 was zł0.92. Hence, Mabion's Price-to-Free-Cash-Flow Ratio for today is 10.95.

The historical rank and industry rank for Mabion's Price-to-Free-Cash-Flow or its related term are showing as below:

WAR:MAB' s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 3.89   Med: 10.82   Max: 25.61
Current: 10.95

During the past 13 years, Mabion's highest Price-to-Free-Cash-Flow Ratio was 25.61. The lowest was 3.89. And the median was 10.82.

WAR:MAB's Price-to-Free-Cash-Flow is ranked better than
79.11% of 225 companies
in the Biotechnology industry
Industry Median: 30.45 vs WAR:MAB: 10.95

Mabion's Free Cash Flow per Share for the three months ended in Sep. 2024 was zł-0.18. Its Free Cash Flow per Share for the trailing twelve months (TTM) ended in was zł0.92.

During the past 12 months, the average Free Cash Flow per Share Growth Rate of Mabion was -57.50% per year. During the past 3 years, the average Free Cash Flow per Share Growth Rate was 3.90% per year.

During the past 13 years, Mabion's highest 3-Year average Free Cash Flow per Share Growth Rate was 31.40% per year. The lowest was -303.60% per year. And the median was -5.80% per year.


Mabion Price-to-Free-Cash-Flow Historical Data

The historical data trend for Mabion's Price-to-Free-Cash-Flow can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Mabion Price-to-Free-Cash-Flow Chart

Mabion Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Price-to-Free-Cash-Flow
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - 15.35 -

Mabion Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Price-to-Free-Cash-Flow Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 7.81 - - 23.21 17.97

Competitive Comparison of Mabion's Price-to-Free-Cash-Flow

For the Biotechnology subindustry, Mabion's Price-to-Free-Cash-Flow, along with its competitors' market caps and Price-to-Free-Cash-Flow data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Mabion's Price-to-Free-Cash-Flow Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Mabion's Price-to-Free-Cash-Flow distribution charts can be found below:

* The bar in red indicates where Mabion's Price-to-Free-Cash-Flow falls into.


;
;

Mabion Price-to-Free-Cash-Flow Calculation

Mabion's Price-to-Free-Cash-Flow ratio for today is calculated as

Price-to-Free-Cash-Flow Ratio=Share Price/ Free Cash Flow per Share (TTM)
=10.12/0.924
=10.95

Mabion's Share Price of today is zł10.12.
Mabion's Free Cash Flow per Share for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was zł0.92.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

Price-to-Free-Cash-Flow Ratio=Market Cap/Free Cash Flow

Mabion  (WAR:MAB) Price-to-Free-Cash-Flow Explanation

Free Cash Flow is considered more important than earnings by value investors. The reason is because, in principle, only the net cash that can be taken from the business belongs to shareholders. This Free Cash Flow can be used to grow the business, reduce debt or return to shareholders in dividends or share buybacks.

In a DCF Calculation Free Cash Flow is used to determine the intrinsic value of companies.


Be Aware

In real business, Free Cash Flow can be affected by the change in accounts receivable, accounts payable, management's decision on expansion, etc. Therefore, investors should look at the Free Cash Flow over the longer term. Long-term average of Free Cash Flow is a more reliable indicator for real free cash flow.


Mabion Price-to-Free-Cash-Flow Related Terms

Thank you for viewing the detailed overview of Mabion's Price-to-Free-Cash-Flow provided by GuruFocus.com. Please click on the following links to see related term pages.


Mabion Business Description

Industry
Traded in Other Exchanges
N/A
Address
ul. Gen. Mariana Langiewicza 60, Konstantynow Lodzki, POL, 95-050
Mabion SA is a Polish biotechnology company focused on developing and launching modern biotechnology drugs based on monoclonal antibody technology. The drugs developed by the company are targeted treatments, characterized by the drug's ability to recognize the factor causing cancer and interact with this factor only. The company is working on the development of its main priority drug, referred to as the MabionCD20 drug. The therapeutic uses of MabionCD20 are for Non-Hodgkin's lymphoma, Leukemia, and Rheumatoid Arthritis.

Mabion Headlines